Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan in migraine.

Hans-Christoph Diener1

  • 1Department of Neurology, University of Essen, Hufelandstr. 55, D45122 Essen, Germany. h.diener@uni-essen.de

Expert Review of Neurotherapeutics
|April 28, 2005
PubMed
Summary

Eletriptan effectively treats acute migraine attacks, offering superior efficacy compared to other treatments. Early intervention with eletriptan for mild headaches shows high sustained pain-free rates and good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Headache·2021
Same author

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Circulation·2021
Same author

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.

Cephalalgia : an international journal of headache·2021
Same author

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Journal of arrhythmia·2021
Same author

MMW Fortschritte der Medizin·2021
Same author

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.

Annals of neurology·2021

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a prevalent, disabling neurological condition with a significant gap between clinical practice guidelines and real-world application.
  • Eletriptan is a selective 5-HT(1B/1D) receptor agonist with favorable pharmacokinetics and cranial selectivity.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of eletriptan for acute migraine treatment.
  • To compare eletriptan's effectiveness against other migraine therapies.

Main Methods:

  • Conducted extensive double-blind, placebo-controlled, head-to-head clinical trials.
  • Assessed efficacy in acute migraine treatment and early intervention for mild headaches.

Main Results:

  • Eletriptan demonstrated superior efficacy compared to ergotamine/caffeine and selected oral triptans.
  • Early treatment of mild headaches with eletriptan resulted in high sustained pain-free rates.
  • Eletriptan exhibited a favorable tolerability profile, comparable to placebo in early treatment.

Conclusions:

  • Eletriptan is a highly effective and well-tolerated option for the acute treatment of migraine.
  • Its efficacy and safety profile support its consideration as a first-line migraine therapy.

Related Experiment Videos